查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1760899

全球性行为感染传染病（STD）药物市场

Sexually Transmitted Diseases (STDs) Drug
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 196 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

到 2030 年，全球性行为感染传染病 (STD) 药物市场规模将达到 1,236 亿美元

全球性行为感染传染病 (STD) 药物市场规模预计在 2024 年为 722 亿美元，到 2030 年将达到 1,236 亿美元，在 2024-2030 年的分析期内，复合年增长率为 9.4%。 HPV 是本报告分析的细分市场之一，预计其复合年增长率为 9.8%，到分析期结束时规模将达到 743 亿美元。披衣菌感染细分市场在分析期间的复合年增长率预计为 8.7%。

美国市场规模估计为 191 亿美元，中国市场预计复合年增长率为 12.9%

2024年，美国性行为感染(STD) 药物市场规模估计为191亿美元。预计到2030年，作为世界第二大经济体的中国市场规模将达到274亿美元，在2024-2030年的分析期内，复合年增长率为12.9%。其他值得关注的区域市场包括日本和加拿大，预计在分析期间内，这两个市场的复合年增长率分别为6.9%和7.2%。在欧洲，预计德国市场的复合年增长率约为7.2%。

全球性行为感染传染病（STD）药物市场－主要趋势与驱动因素摘要

什么是性行为感染传染病 (STD) 药物？为什么它们在现代医疗保健中很重要？

性行为感染传染病 (STD)，也称为性感染疾病(STI)，是主要透过性接触传播的感染疾病。常见的 STD 包括披衣菌感染、淋病、梅毒、生殖器疱疹、人类乳突病毒 (HPV) 和 HIV/AIDS。用于治疗这些感染疾病的药物种类繁多，包括抗真菌药物和抗逆转录病毒药物，每种药物都针对特定的病原体或与疾病相关的症状。 STD 药物在控制这些感染疾病、降低感染率和预防长期健康併发症（如不孕症、器官损害和增加对其他感染疾病的易感性）方面发挥关键作用。及时有效地治疗 STD 对于遏制这些疾病的传播和改善公共卫生结果至关重要。

由于感染率上升和人们对性健康的认识不断提高，全球性传染病药物市场变得越来越重要。世界卫生组织 (WHO) 估计，全世界每天有超过 100 万人感染性传染病，凸显了对有效治疗和预防策略的迫切需求。高风险行为的盛行、性健康教育的不足以及某些地区获得医疗保健服务的机会有限进一步推动了市场的发展。此外，正在进行的生产更有效、抗药性更低的药物的研究和开发也促进了市场扩张。随着新的抗药性细菌和病毒株的出现，开发创新治疗方法变得比以往任何时候都更加重要。因此，性传染病药物市场将在应对全球性行为感染负担和促进全球性健康方面发挥关键作用。

科技进步如何影响治疗性病的药物的发展？

科技进步显着促进了性传染病药物的研发和疗效，从而能够研发出副作用更少、疗效更佳的治疗方法。该领域的一项重大进展是开发针对抗药性病原体的新一代抗生素和抗病毒药物。抗药性是治疗淋病和梅毒等细菌性性传染病的一大挑战。多重抗药性菌株的出现使得许多传统抗生素失效，因此亟需开发能够克服抗药性机制的新型药物。研究人员正在探索新的抗生素组合和新的药物输送系统，例如基于奈米颗粒的製剂，以提高药物渗透性和对抗抗药性细菌的疗效。这些创新对于维持性传染病治疗的有效性和遏制抗药性感染的传播至关重要。

另一项重大进展是标靶治疗和个人化医疗方法在性传染病（STD）治疗中的应用。随着我们对各种感染疾病分子机制的理解不断加深，研究人员正在开发特异性针对参与病原体复製和存活的蛋白质和路径的药物。例如，抑制特定病毒酶活性的标靶抗病毒疗法，例如用于治疗HIV的蛋白酶抑制剂和用于治疗疱疹的解旋酶抑制剂，提供了更有效、更有针对性的治疗方案。此外，CRISPR-Cas9等基因编辑技术的进步，透过直接靶向和修改宿主细胞内的病毒DNA，为治癒病毒感染开闢了新的可能性。儘管这些技术仍处于研究的早期阶段，但它们有可能改变HIV和疱疹等慢性病毒感染疾病的治疗模式。

此外，长效製剂和单剂量治疗的开发正在提高患者的依从性和便利性。长效注射剂，例如用于预防和治疗爱滋病毒的卡博特韦，可以将给药频率从每天减少到每月甚至每季度，使患者更容易坚持治疗方法。针对某些细菌性性传染病的单剂量治疗，例如用于治疗披衣菌感染的阿奇霉素，为控制感染疾病提供了一种方便有效的解决方案，特别是在医疗保健机会有限的地区。这些技术和科学进步不仅提高了性传染病治疗的有效性和便利性，而且还扩大了医疗保健提供者可用的治疗选择范围，为性性行为感染患者提供更全面和个人化的护理铺平了道路。

哪些因素推动了不同地区和族群采用性病药物治疗？

性传染病药物的采用受到多种关键因素的推动，包括感染率上升、认识和检测的加强以及全球卫生倡议的实施。其中一个关键驱动因素是全球性传染病盛行率上升，尤其是在年轻人和高风险族群中。性行为的变化，例如性伴侣增加和避孕器使用不坚持，正在加剧性传染病的传播。为此，医疗保健提供者和公共卫生机构优先考虑使用有效的性传染病药物，以遏制感染的传播并减轻医疗保健系统的负担。此外，人们对定期性传染病检测的认识和接受度不断提高也支持了感染的早期诊断和治疗，从而导致对性传染病药物的需求增加。这种趋势在北美和欧洲等已开发地区尤其明显，这些地区开展了广泛的筛检计划和宣传宣传活动，鼓励个人及时寻求治疗。

推动性传染病药物普及的另一个重要因素是旨在降低性传染病盛行率和改善治疗可近性的全球卫生倡议的实施。世界卫生组织和联合国爱滋病规划署等治疗组织正积极致力于遏制性传染病的传播，例如透过《全球卫生部门性行为感染传染病倡议》和爱滋病毒治疗与预防「90-90-90」目标等措施。这些项目强调检测、治疗和预防的重要性，并提供资金和资源以改善治疗可近性，尤其是在中低收入国家。因此，更多人能够获得诊断服务和救命药物，促进了这些地区性传染病药物的普及。此外，学名药供应的日益充足也使治疗费用更加可负担，进一步鼓励了资源匮乏地区的性传染病患者采用该药物。

此外，人们日益关注预防性疗法，例如用于预防爱滋病毒的暴露前预防 (PrEP)，这也推动了对性传染病药物的需求。 PrEP 是一种定期服用抗逆转录病毒药物来预防爱滋病毒感染的方法，它已成为高风险族群中一种有效的预防策略，越来越受欢迎。 PrEP 在减少新的爱滋病毒感染方面的成功促使许多国家采用它，製药公司也对此做出了回应，开发了疗效更好、更方便的新型 PrEP 製剂。这种预防措施不仅限于爱滋病毒，还透过开发疫苗和预防性治疗应用于其他性传染病。例如， 人类乳突病毒(HPV)疫苗可以预防与生殖器湿疣和子宫颈癌相关的某些人类乳突病毒株，已被广泛用作预防措施。这种预防策略是对传统治疗方法的补充，透过降低感染疾病发生率和促进更好的性健康结果，促进了整个性传染病药物市场的成长。

是什么推动了全球性病市场的成长？

全球性传染病药物市场的成长受到多种因素的推动，包括全球感染率上升、研发投入增加以及对解决抗药性的日益关注。主要成长要素之一是全球性传染病盛行率的上升。世界卫生组织估计，每年有超过 3.76 亿例可治疗性传染病（披衣菌感染、淋病、梅毒、滴虫病等）新发病例。这些感染疾病会导致併发症并造成负担，增加了对有效治疗的需求。此外，疱疹和爱滋病毒/爱滋病等病毒性性传染病的盛行率不断上升进一步促进了市场的成长。随着性传染病数量的持续上升，医疗保健提供者和政府正在投资扩大检测和治疗服务的覆盖面，这反过来又推动了对性传染病药物的需求。

市场成长的另一个主要驱动力是製药公司和研究机构不断增加的研发投入。随着人们对淋病等细菌性性传染病抗生素抗药性的担忧日益加剧，迫切需要新的有效治疗方案。製药公司正在积极开发新型抗生素，并探索新的作用机制来应对抗药性菌株。此外，长效製剂和联合治疗的研究正在提供新的治疗选择，以提高患者的依从性并降低抗药性风险。性传染病疫苗的开发，例如正在进行的疱疹和爱滋病毒疫苗研究，也透过扩大预防疗法的范围促进了市场发展。此外，远端医疗平台和家用检测套组等数位健康技术的整合，正在提高治疗的可近性，促进早期诊断和治疗，从而支持整个性传染病药物市场的成长。

此外，对改善性健康和减少围绕性传染病的耻辱感的关注也在推动市场成长。公共卫生宣传活动和宣传工作提高了人们对定期筛检、安全性行为和及时治疗重要性的认识，鼓励更多人寻求治疗。这种态度的转变正在推动对性传染病药物的需求，特别是在感染率高的地区。此外，学名药的出现使得性传染病药物更容易取得且价格更实惠，有助于打开已开发经济体和新兴经济体的市场。随着这些因素持续影响全球医疗保健格局，性传染病药物市场预计将因感染率上升、研发工作持续进行以及全球为改善治疗和预防选择可及性而做出的不断努力而持续增长。

部分

疾病类型（HPV、披衣菌感染、HIV/AIDS、淋病、生殖器疱疹、梅毒、其他疾病类型）、治疗方法（抗生素、抗病毒/抗逆转录病毒、疫苗、其他治疗方法）

调查企业范例（共46家企业）

  • AbbVie, Inc.
  • Bayer Healthcare AG
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Pfizer, Inc.

人工智慧集成

全球产业分析师正在利用可操作的专家内容和人工智慧工具改变市场和竞争情报。

Global 特定产业SLM 的典型规范，而是建立了一个从全球专家收集的内容库，其中包括视讯录影、部落格、搜寻引擎研究以及大量的公司、产品/服务和市场数据。

关税影响係数

全球产业分析师根据公司总部所在国家、製造地、进出口状况（成品和原始OEM）预测其竞争态势的变化。这种复杂且多面向的市场动态预计将以多种方式影响竞争对手，包括销货成本成本 (COGS) 上升、盈利下降、供应链重组以及其他微观和宏观市场动态。

目录

第一章调查方法

第二章执行摘要

  • 市场概览
  • 主要企业
  • 市场趋势和驱动因素
  • 全球市场展望

第三章市场分析

  • 美国
  • 加拿大
  • 日本
  • 中国
  • 欧洲
  • 法国
  • 德国
  • 义大利
  • 英国
  • 西班牙
  • 俄罗斯
  • 其他欧洲国家
  • 亚太地区
  • 澳洲
  • 印度
  • 韩国
  • 其他亚太地区
  • 拉丁美洲
  • 阿根廷
  • 巴西
  • 墨西哥
  • 其他拉丁美洲
  • 中东
  • 伊朗
  • 以色列
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 其他中东地区
  • 非洲

第四章 比赛

简介目录
Product Code: MCP16773

Global Sexually Transmitted Diseases (STDs) Drug Market to Reach US$123.6 Billion by 2030

The global market for Sexually Transmitted Diseases (STDs) Drug estimated at US$72.2 Billion in the year 2024, is expected to reach US$123.6 Billion by 2030, growing at a CAGR of 9.4% over the analysis period 2024-2030. HPV, one of the segments analyzed in the report, is expected to record a 9.8% CAGR and reach US$74.3 Billion by the end of the analysis period. Growth in the Chlamydia segment is estimated at 8.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$19.1 Billion While China is Forecast to Grow at 12.9% CAGR

The Sexually Transmitted Diseases (STDs) Drug market in the U.S. is estimated at US$19.1 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$27.4 Billion by the year 2030 trailing a CAGR of 12.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 6.9% and 7.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 7.2% CAGR.

Global Sexually Transmitted Diseases (STDs) Drug Market - Key Trends & Drivers Summarized

What Are Sexually Transmitted Diseases (STDs) Drugs and Why Are They Critical in Modern Healthcare?

Sexually transmitted diseases (STDs), also known as sexually transmitted infections (STIs), are infections that are primarily spread through sexual contact. Common STDs include chlamydia, gonorrhea, syphilis, genital herpes, human papillomavirus (HPV), and HIV/AIDS. The treatment of these infections relies on a range of pharmaceutical drugs, including antibiotics, antivirals, antifungals, and antiretrovirals, each designed to target specific pathogens or symptoms associated with the disease. STD drugs play a crucial role in managing these infections, reducing transmission rates, and preventing long-term health complications such as infertility, organ damage, or increased susceptibility to other infections. Timely and effective treatment of STDs is essential for controlling the spread of these diseases and improving public health outcomes.

The global STD drugs market is becoming increasingly significant due to rising infection rates and growing awareness of sexual health. The World Health Organization (WHO) estimates that over 1 million STIs are acquired daily worldwide, highlighting the urgent need for effective treatment and prevention strategies. The market is further driven by the increasing prevalence of high-risk behaviors, inadequate sexual health education, and limited access to healthcare services in certain regions. In addition, the ongoing research and development efforts to create more effective and less resistant drugs are contributing to the expansion of the market. With the emergence of new drug-resistant strains of bacteria and viruses, the development of innovative therapies is becoming more critical than ever. As a result, the STD drugs market is poised to play a pivotal role in combating the global burden of sexually transmitted infections and promoting better sexual health worldwide.

How Are Technological and Scientific Advancements Shaping the Development of STD Drugs?

Technological and scientific advancements are significantly enhancing the development and efficacy of STD drugs, enabling the creation of more effective treatments with fewer side effects. One of the key advancements in this field is the development of next-generation antibiotics and antivirals that target drug-resistant strains of pathogens. Drug resistance has become a major challenge in the treatment of bacterial STDs such as gonorrhea and syphilis. The emergence of multi-drug-resistant strains has rendered many traditional antibiotics ineffective, necessitating the development of new classes of drugs that can overcome resistance mechanisms. Researchers are exploring new antibiotic combinations, as well as novel drug delivery systems such as nanoparticle-based formulations, to improve drug penetration and effectiveness against resistant bacteria. These innovations are crucial for maintaining the effectiveness of STD treatments and reducing the spread of resistant infections.

Another significant advancement is the use of targeted therapies and personalized medicine approaches in STD treatment. With a deeper understanding of the molecular mechanisms underlying various infections, researchers are developing drugs that specifically target the proteins or pathways involved in the replication and survival of the pathogens. For instance, targeted antiviral therapies that inhibit the activity of specific viral enzymes, such as protease inhibitors for HIV or helicase inhibitors for herpes, are providing more effective and focused treatment options. In addition, advancements in gene editing technologies, such as CRISPR-Cas9, are opening up new possibilities for curing viral infections by directly targeting and modifying viral DNA within host cells. Although these technologies are still in the early stages of research, they hold the potential to revolutionize the treatment landscape for chronic viral infections such as HIV and herpes.

Furthermore, the development of long-acting formulations and single-dose treatments is enhancing patient compliance and convenience. Long-acting injectables, such as cabotegravir for HIV prevention and treatment, offer the potential to reduce the frequency of dosing from daily to monthly or even quarterly, making it easier for patients to adhere to their treatment regimens. Single-dose treatments for certain bacterial STDs, such as azithromycin for chlamydia, provide a convenient and effective solution for managing infections, particularly in regions with limited access to healthcare. These technological and scientific advancements are not only improving the effectiveness and convenience of STD treatments but are also expanding the scope of therapeutic options available to healthcare providers, paving the way for more comprehensive and personalized care for individuals affected by sexually transmitted infections.

What Factors Are Driving the Adoption of STD Drugs Across Different Regions and Populations?

The adoption of STD drugs is being driven by several key factors, including rising infection rates, increased awareness and testing, and the implementation of global health initiatives. One of the primary drivers is the rising incidence of STDs globally, particularly among young adults and high-risk populations. Changes in sexual behaviors, such as increased number of sexual partners and inconsistent use of protection, are contributing to the spread of STDs. In response, healthcare providers and public health organizations are prioritizing the use of effective STD drugs to control the spread of infections and reduce the burden on healthcare systems. The growing awareness and acceptance of regular STD testing are also supporting the early diagnosis and treatment of infections, leading to higher demand for STD drugs. This trend is particularly noticeable in developed regions such as North America and Europe, where extensive screening programs and awareness campaigns are encouraging individuals to seek timely treatment.

Another significant factor driving the adoption of STD drugs is the implementation of global health initiatives aimed at reducing the prevalence of STDs and improving access to treatment. Organizations such as the WHO and UNAIDS are actively working to combat the spread of STDs through initiatives like the Global Health Sector Strategy on Sexually Transmitted Infections and the “90-90-90” targets for HIV treatment and prevention. These programs emphasize the importance of testing, treatment, and prevention, and they provide funding and resources to improve access to care, particularly in low- and middle-income countries. As a result, more people are gaining access to diagnostic services and life-saving medications, contributing to the growing adoption of STD drugs in these regions. Moreover, the increasing availability of generic drugs is making treatment more affordable, further supporting adoption in resource-limited settings.

Additionally, the rising focus on preventive therapies, such as pre-exposure prophylaxis (PrEP) for HIV prevention, is driving demand for STD drugs. PrEP, which involves taking antiretroviral drugs regularly to prevent HIV infection, is gaining popularity as an effective prevention strategy among high-risk populations. The success of PrEP in reducing new HIV infections is encouraging its adoption in many countries, and pharmaceutical companies are responding by developing new PrEP formulations with improved efficacy and convenience. This focus on prevention is not limited to HIV but is also being applied to other STDs through the development of vaccines and prophylactic treatments. For example, the HPV vaccine, which prevents certain strains of the human papillomavirus linked to genital warts and cervical cancer, is being widely adopted as a preventive measure. These preventive strategies are complementing traditional treatment approaches and contributing to the overall growth of the STD drugs market by reducing the incidence of infections and promoting better sexual health outcomes.

What Is Driving the Growth of the Global STD Drugs Market?

The growth in the global STD drugs market is driven by several factors, including rising global infection rates, increasing investments in research and development, and the growing focus on addressing drug resistance. One of the primary growth drivers is the rising prevalence of STDs worldwide. The WHO estimates that there are over 376 million new cases of curable STDs (such as chlamydia, gonorrhea, syphilis, and trichomoniasis) annually. The high burden of these infections, coupled with their potential complications, is driving the demand for effective treatments. Additionally, the increasing incidence of viral STDs such as herpes and HIV/AIDS is further contributing to market growth. As the number of people affected by STDs continues to rise, healthcare providers and governments are investing in expanding access to testing and treatment services, which is boosting the demand for STD drugs.

Another significant driver of market growth is the increasing investment in research and development by pharmaceutical companies and research institutions. With the growing concern over antibiotic resistance in bacterial STDs like gonorrhea, there is a pressing need for new and effective treatment options. Pharmaceutical companies are actively developing new antibiotics and exploring novel mechanisms of action to address resistant strains. Additionally, research into long-acting formulations and combination therapies is providing new treatment options that improve patient adherence and reduce the risk of resistance. The development of vaccines for STDs, such as ongoing research into vaccines for herpes and HIV, is also contributing to market growth by expanding the scope of preventive therapies. Furthermore, the integration of digital health technologies, such as telemedicine platforms and at-home testing kits, is enhancing access to care and facilitating early diagnosis and treatment, supporting the overall growth of the STD drugs market.

Moreover, the focus on improving sexual health and reducing stigma around STDs is driving market growth. Public health campaigns and advocacy efforts are raising awareness of the importance of regular screening, safe sexual practices, and timely treatment, encouraging more people to seek care. This shift in attitudes is increasing the demand for STD drugs, particularly in regions with high infection rates. Additionally, the availability of generic and over-the-counter (OTC) treatments is making STD drugs more accessible and affordable, supporting market growth in both developed and developing regions. As these factors continue to shape the global healthcare landscape, the STD drugs market is expected to experience sustained growth, driven by rising infection rates, ongoing research and development, and increasing efforts to improve access to treatment and prevention options worldwide.

SCOPE OF STUDY:

The report analyzes the Sexually Transmitted Diseases (STDs) Drug market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Disease Type (HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital Herpes, Syphilis, Other Disease Types); Therapy (Antibiotics, Antivirals / Antiretrovirals, Vaccines, Other Therapies)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 46 Featured) -

  • AbbVie, Inc.
  • Bayer Healthcare AG
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Pfizer, Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Sexually Transmitted Diseases (STDs) Drug - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of STDs Globally Spurs Demand for Effective Therapeutics
    • Increasing Awareness and Early Diagnosis of STDs Expands Addressable Market for Drug Therapies
    • Rising Government and NGO Efforts for STD Prevention Bodes Well for Market Growth
    • Development of Innovative Antibiotics and Antivirals Propels Market Growth for STD Drugs
    • Focus on Addressing Antibiotic Resistance Issues in STD Treatment Supports Market Expansion
    • Emergence of Vaccines for STDs Creates New Opportunities in the Market
    • Focus on Reducing Stigma and Improving Access to Treatment Propels Market Demand
    • Increased Availability of Over-the-Counter STD Treatment Options Bodes Well for Market Growth
    • Rising Demand for Home-Based and Rapid Diagnostic Kits Supports Growth of STD Drug Market
    • Focus on Digital Health Platforms and Telemedicine for STD Treatment Drives Market Growth
    • Emergence of Long-Acting Injectables and Implants Creates New Market Opportunities
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Sexually Transmitted Diseases (STDs) Drug Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Sexually Transmitted Diseases (STDs) Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for HPV by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for HPV by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for HPV by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Chlamydia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Chlamydia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Chlamydia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for HIV / AIDS by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for HIV / AIDS by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for HIV / AIDS by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Gonorrhea by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Gonorrhea by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Gonorrhea by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Genital herpes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Genital herpes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Genital herpes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Syphilis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Syphilis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Syphilis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Other Disease Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Antibiotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Antibiotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Antibiotics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Antivirals / Antiretrovirals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Antivirals / Antiretrovirals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Antivirals / Antiretrovirals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: World 15-Year Perspective for Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Other Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Other Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: World 15-Year Perspective for Other Therapies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Sexually Transmitted Diseases (STDs) Drug Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 38: USA Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: USA 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Disease Type - Percentage Breakdown of Value Sales for HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 41: USA Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: USA 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Therapy - Percentage Breakdown of Value Sales for Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Canada 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Disease Type - Percentage Breakdown of Value Sales for HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Canada 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Therapy - Percentage Breakdown of Value Sales for Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies for the Years 2015, 2025 & 2030
  • JAPAN
    • Sexually Transmitted Diseases (STDs) Drug Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Japan 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Disease Type - Percentage Breakdown of Value Sales for HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Japan 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Therapy - Percentage Breakdown of Value Sales for Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies for the Years 2015, 2025 & 2030
  • CHINA
    • Sexually Transmitted Diseases (STDs) Drug Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 56: China Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: China Historic Review for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: China 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Disease Type - Percentage Breakdown of Value Sales for HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 59: China Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: China 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Therapy - Percentage Breakdown of Value Sales for Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies for the Years 2015, 2025 & 2030
  • EUROPE
    • Sexually Transmitted Diseases (STDs) Drug Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 63: Europe Historic Review for Sexually Transmitted Diseases (STDs) Drug by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: Europe 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 65: Europe Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Europe Historic Review for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Europe 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Disease Type - Percentage Breakdown of Value Sales for HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Europe 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Therapy - Percentage Breakdown of Value Sales for Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies for the Years 2015, 2025 & 2030
  • FRANCE
    • Sexually Transmitted Diseases (STDs) Drug Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 71: France Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: France Historic Review for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: France 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Disease Type - Percentage Breakdown of Value Sales for HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 74: France Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: France Historic Review for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: France 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Therapy - Percentage Breakdown of Value Sales for Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies for the Years 2015, 2025 & 2030
  • GERMANY
    • Sexually Transmitted Diseases (STDs) Drug Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 77: Germany Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Germany Historic Review for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Germany 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Disease Type - Percentage Breakdown of Value Sales for HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 80: Germany Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Germany Historic Review for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Germany 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Therapy - Percentage Breakdown of Value Sales for Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 83: Italy Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Italy Historic Review for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Italy 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Disease Type - Percentage Breakdown of Value Sales for HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 86: Italy Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Italy Historic Review for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Italy 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Therapy - Percentage Breakdown of Value Sales for Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Sexually Transmitted Diseases (STDs) Drug Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 89: UK Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: UK Historic Review for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: UK 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Disease Type - Percentage Breakdown of Value Sales for HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 92: UK Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: UK Historic Review for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: UK 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Therapy - Percentage Breakdown of Value Sales for Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 95: Spain Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Spain Historic Review for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Spain 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Disease Type - Percentage Breakdown of Value Sales for HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 98: Spain Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Spain Historic Review for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Spain 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Therapy - Percentage Breakdown of Value Sales for Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 101: Russia Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Russia Historic Review for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Russia 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Disease Type - Percentage Breakdown of Value Sales for HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 104: Russia Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Russia Historic Review for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Russia 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Therapy - Percentage Breakdown of Value Sales for Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 107: Rest of Europe Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Rest of Europe Historic Review for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Rest of Europe 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Disease Type - Percentage Breakdown of Value Sales for HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 110: Rest of Europe Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Rest of Europe Historic Review for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Rest of Europe 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Therapy - Percentage Breakdown of Value Sales for Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Sexually Transmitted Diseases (STDs) Drug Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 113: Asia-Pacific Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 114: Asia-Pacific Historic Review for Sexually Transmitted Diseases (STDs) Drug by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Asia-Pacific 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 116: Asia-Pacific Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Asia-Pacific Historic Review for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: Asia-Pacific 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Disease Type - Percentage Breakdown of Value Sales for HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 119: Asia-Pacific Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Asia-Pacific Historic Review for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: Asia-Pacific 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Therapy - Percentage Breakdown of Value Sales for Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Sexually Transmitted Diseases (STDs) Drug Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 122: Australia Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Australia Historic Review for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: Australia 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Disease Type - Percentage Breakdown of Value Sales for HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 125: Australia Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Australia Historic Review for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Australia 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Therapy - Percentage Breakdown of Value Sales for Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies for the Years 2015, 2025 & 2030
  • INDIA
    • Sexually Transmitted Diseases (STDs) Drug Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 128: India Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: India Historic Review for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: India 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Disease Type - Percentage Breakdown of Value Sales for HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 131: India Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: India Historic Review for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: India 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Therapy - Percentage Breakdown of Value Sales for Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 134: South Korea Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: South Korea Historic Review for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: South Korea 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Disease Type - Percentage Breakdown of Value Sales for HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 137: South Korea Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: South Korea Historic Review for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: South Korea 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Therapy - Percentage Breakdown of Value Sales for Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 140: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Rest of Asia-Pacific Historic Review for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Rest of Asia-Pacific 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Disease Type - Percentage Breakdown of Value Sales for HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 143: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Rest of Asia-Pacific Historic Review for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Rest of Asia-Pacific 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Therapy - Percentage Breakdown of Value Sales for Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Sexually Transmitted Diseases (STDs) Drug Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 146: Latin America Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 147: Latin America Historic Review for Sexually Transmitted Diseases (STDs) Drug by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Latin America 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 149: Latin America Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Latin America Historic Review for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Latin America 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Disease Type - Percentage Breakdown of Value Sales for HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 152: Latin America Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Latin America Historic Review for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Latin America 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Therapy - Percentage Breakdown of Value Sales for Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 155: Argentina Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Argentina Historic Review for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Argentina 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Disease Type - Percentage Breakdown of Value Sales for HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 158: Argentina Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Argentina Historic Review for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Argentina 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Therapy - Percentage Breakdown of Value Sales for Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 161: Brazil Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Brazil Historic Review for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Brazil 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Disease Type - Percentage Breakdown of Value Sales for HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 164: Brazil Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Brazil Historic Review for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Brazil 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Therapy - Percentage Breakdown of Value Sales for Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 167: Mexico Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Mexico Historic Review for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Mexico 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Disease Type - Percentage Breakdown of Value Sales for HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 170: Mexico Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Mexico Historic Review for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Mexico 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Therapy - Percentage Breakdown of Value Sales for Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 173: Rest of Latin America Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Rest of Latin America Historic Review for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Rest of Latin America 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Disease Type - Percentage Breakdown of Value Sales for HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 176: Rest of Latin America Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Rest of Latin America Historic Review for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Rest of Latin America 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Therapy - Percentage Breakdown of Value Sales for Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Sexually Transmitted Diseases (STDs) Drug Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 179: Middle East Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 180: Middle East Historic Review for Sexually Transmitted Diseases (STDs) Drug by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Middle East 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 182: Middle East Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Middle East Historic Review for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Middle East 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Disease Type - Percentage Breakdown of Value Sales for HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 185: Middle East Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Middle East Historic Review for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Middle East 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Therapy - Percentage Breakdown of Value Sales for Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 188: Iran Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Iran Historic Review for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Iran 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Disease Type - Percentage Breakdown of Value Sales for HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 191: Iran Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Iran Historic Review for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Iran 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Therapy - Percentage Breakdown of Value Sales for Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 194: Israel Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Israel Historic Review for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Israel 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Disease Type - Percentage Breakdown of Value Sales for HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 197: Israel Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Israel Historic Review for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Israel 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Therapy - Percentage Breakdown of Value Sales for Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 200: Saudi Arabia Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Saudi Arabia Historic Review for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Saudi Arabia 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Disease Type - Percentage Breakdown of Value Sales for HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 203: Saudi Arabia Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Saudi Arabia Historic Review for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Saudi Arabia 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Therapy - Percentage Breakdown of Value Sales for Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 206: UAE Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: UAE Historic Review for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: UAE 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Disease Type - Percentage Breakdown of Value Sales for HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 209: UAE Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: UAE Historic Review for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: UAE 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Therapy - Percentage Breakdown of Value Sales for Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 212: Rest of Middle East Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Rest of Middle East Historic Review for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Rest of Middle East 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Disease Type - Percentage Breakdown of Value Sales for HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 215: Rest of Middle East Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Rest of Middle East Historic Review for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 217: Rest of Middle East 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Therapy - Percentage Breakdown of Value Sales for Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies for the Years 2015, 2025 & 2030
  • AFRICA
    • Sexually Transmitted Diseases (STDs) Drug Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 218: Africa Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Africa Historic Review for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 220: Africa 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Disease Type - Percentage Breakdown of Value Sales for HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 221: Africa Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Africa Historic Review for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 223: Africa 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Therapy - Percentage Breakdown of Value Sales for Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies for the Years 2015, 2025 & 2030

IV. COMPETITION